Breaking News, Collaborations & Alliances

GenSight Transfers Upstream Phase of LUMEVOQ Manufacturing Process to Catalent

Partnership expected to improve yield and upgrade analytical methods ahead of clinical use and regulatory submissions.

Author Image

By: Charlie Sternberg

Associate Editor

GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies, has transferred the upstream phase of the manufacturing process for LUMEVOQ, its gene therapy candidate product for the rare mitochondrial disease Leber Hereditary Optic Neuropathy (LHON), to its new manufacturing partner, Catalent Inc. Catalent Inc. is the only CDMO with a successfully commercialized gene therapy produced in its facility. Catalent offers gene therapy companies both pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters